CN102292093B - 用于代谢综合症控制的选自绒毛戴星草和莽吉柿的混合物 - Google Patents

用于代谢综合症控制的选自绒毛戴星草和莽吉柿的混合物 Download PDF

Info

Publication number
CN102292093B
CN102292093B CN201080004917.9A CN201080004917A CN102292093B CN 102292093 B CN102292093 B CN 102292093B CN 201080004917 A CN201080004917 A CN 201080004917A CN 102292093 B CN102292093 B CN 102292093B
Authority
CN
China
Prior art keywords
mixture
medicine
dietary supplement
lactone
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080004917.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102292093A (zh
Inventor
冈加·拉吉·古卡拉吉
拉玛·拉吉·古卡拉吉
文卡塔·肯纳卡·兰加·拉吉·古卡拉吉
崔姆尔土卢·古兰扣堤
吉兰·布帕蒂拉吉
克里斯南·森古普塔
文卡塔·克里斯南·拉吉·阿汝李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laila Nutraceuticals
Original Assignee
Laila Nutraceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laila Nutraceuticals filed Critical Laila Nutraceuticals
Publication of CN102292093A publication Critical patent/CN102292093A/zh
Application granted granted Critical
Publication of CN102292093B publication Critical patent/CN102292093B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
CN201080004917.9A 2009-02-02 2010-02-01 用于代谢综合症控制的选自绒毛戴星草和莽吉柿的混合物 Active CN102292093B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN224/CHE/2009 2009-02-02
IN224CH2009 2009-02-02
PCT/IN2010/000053 WO2010100653A2 (en) 2009-02-02 2010-02-01 Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome

Publications (2)

Publication Number Publication Date
CN102292093A CN102292093A (zh) 2011-12-21
CN102292093B true CN102292093B (zh) 2015-01-28

Family

ID=42710066

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080004917.9A Active CN102292093B (zh) 2009-02-02 2010-02-01 用于代谢综合症控制的选自绒毛戴星草和莽吉柿的混合物

Country Status (8)

Country Link
US (3) US9241964B2 (https=)
EP (1) EP2391374B1 (https=)
JP (1) JP2012516842A (https=)
KR (1) KR101682489B1 (https=)
CN (1) CN102292093B (https=)
AU (1) AU2010220058B2 (https=)
CA (1) CA2751227C (https=)
WO (1) WO2010100653A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
ME01898B (me) 2008-08-12 2014-12-20 Zinfandel Pharmaceuticals Inc Metoda za identifikaciju faktora rizika od alchajmerove bolesti
JP2011079752A (ja) * 2009-10-05 2011-04-21 Kracie Home Products Ltd 膵リパーゼ阻害剤並びにそれを含有する飲食品組成物及び医薬品組成物
PH12013500451A1 (en) * 2010-09-11 2013-05-20 Laila Nutraceuticals Sphaeranthus indicus derived ingredients and their compositions for enhancing physical performance and energy levels
JP5976271B2 (ja) * 2010-12-24 2016-08-23 クラシエホームプロダクツ株式会社 リパーゼ阻害剤並びにそれを含有する化粧料、飲食品組成物及び医薬品組成物
AU2012205798B2 (en) 2011-01-10 2016-02-25 Takeda Pharmaceutical Company Limited Methods and drug products for treating Alzheimer's disease
KR101508294B1 (ko) * 2012-07-05 2015-04-07 동국대학교 산학협력단 망고스틴 추출물 또는 감마, 알파 망고스틴을 유효성분으로 포함하는 ｃ형 간염의 예방 또는 치료용 조성물
JP2014034562A (ja) * 2012-08-10 2014-02-24 Lotte Kenko Sangyo:Kk アディポネクチン産生促進剤
WO2014064609A2 (en) * 2012-10-23 2014-05-01 Piramal Enterprises Limited HERBAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF TNF-α MEDIATED DISEASES
US20140377386A1 (en) * 2013-06-19 2014-12-25 Access Business Group International Llc Plant-based inhibitors of ketohexokinase for the support of weight management
JP6511604B2 (ja) * 2013-07-10 2019-05-15 和久 前田 メタボリックシンドローム治療剤の製造方法
CN106361784B (zh) * 2015-07-24 2020-08-14 山酮新药开发股份有限公司 山竹果果壳萃取物用于治疗皮肤疾病的用途
TWI565472B (zh) * 2016-02-02 2017-01-11 基業生物科技股份有限公司 山竹組合物及其製備增進阿茲海默症患者學習能力與記憶的藥物及保健食品之用途
BR112018073483B1 (pt) * 2016-05-21 2022-08-23 Laila Impex Suplementos e composições dietéticas para a melhoria do desempenho físico e dos níveis de energia
CN111773208A (zh) * 2019-09-20 2020-10-16 厦门医学院 藤黄属果实萃取物γ-倒捻子素在制备降血糖及降血压的药物组合物中的应用
CN111758967B (zh) * 2020-07-15 2022-10-11 张兆熙 一种大鲵胶原蛋白肽组合物及其应用
CN118873430B (zh) * 2024-08-16 2025-04-04 诺德溯源(广州)生物科技有限公司 一种敏感肌适用的植物a醇祛皱紧致组合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101304756A (zh) * 2005-09-30 2008-11-12 皮拉马尔生命科学有限公司 用于炎性病症的草药组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3647054B2 (ja) * 1993-11-12 2005-05-11 御木本製薬株式会社 抗酸化剤
JPH09110688A (ja) * 1995-10-13 1997-04-28 Meiji Milk Prod Co Ltd 抗菌剤
FR2774905B1 (fr) * 1998-02-17 2000-06-09 Codif International Sa Utilisation d'une composition cosmetique comportant au moins une substance qui comprend un groupement pyrone
GB9921229D0 (en) * 1999-09-08 1999-11-10 Med Eq As Compositions
JP2002047125A (ja) * 2000-05-26 2002-02-12 Shiseido Co Ltd 皮脂分泌抑制用皮膚外用剤
DE60309075D1 (de) * 2003-03-31 2006-11-23 Council Scient Ind Res Verfahren zur herstellung hypoglykämischer lebensmittel und formulierungen daraus
ES2559777T3 (es) * 2004-03-17 2016-02-15 Nestec S.A. Composiciones y métodos para reducir o prevenir la obesidad
JP4247154B2 (ja) * 2004-03-18 2009-04-02 有限会社 坂本薬草園 ＰＰＡＲγ活性化剤
JP5140231B2 (ja) * 2004-04-08 2013-02-06 株式会社ロッテ ＩκＢキナーゼ阻害剤
WO2006134609A2 (en) * 2005-06-16 2006-12-21 Mmi Corporation Novel anticancer agent, methods for obtaining the same and pharmaceutical compositions thereof
EA014070B1 (ru) * 2005-09-30 2010-08-30 Пирамал Лайф Сайнсиз Лимитед Применение растительной композиции для лечения воспалительных нарушений
FR2908310B1 (fr) 2006-11-14 2009-07-10 Phytodia Produits agonistes de tgr5 et leurs applications
WO2008093848A1 (ja) 2007-02-02 2008-08-07 Sunstar Inc. ホスファチジルコリンを含有する炎症マーカー低減組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101304756A (zh) * 2005-09-30 2008-11-12 皮拉马尔生命科学有限公司 用于炎性病症的草药组合物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
水果、蔬菜、调料中脂肪酸合酶抑制剂的筛选;郝杰等;《生命科学仪器》;20081115(第11期);22-30 *
治疗癌症、调节免疫的草药混合物;陈蕙芳;《国外医药(植物药分册)》;20081115(第06期);281 *
莽吉柿果皮中脂肪酸及其它脂溶性成分的GC-MS分析;赵岩等;《特产研究》;20070330(第01期);65-67 *
莽吉柿果皮提取物对实验性高脂血症大鼠血脂的影响;赵岩等;《特产研究》;20070615(第02期);55-57 *
莽吉柿药理活性的研究概况;夏星;《广西中医学院学报》;20090915(第03期);79-81 *
陈蕙芳.治疗癌症、调节免疫的草药混合物.《国外医药(植物药分册)》.2008,(第06期), *

Also Published As

Publication number Publication date
US10471114B2 (en) 2019-11-12
CA2751227A1 (en) 2010-09-10
EP2391374A4 (en) 2014-01-08
EP2391374A2 (en) 2011-12-07
JP2012516842A (ja) 2012-07-26
WO2010100653A8 (en) 2011-08-04
KR20110122158A (ko) 2011-11-09
US9241964B2 (en) 2016-01-26
EP2391374B1 (en) 2018-11-14
US20130136809A1 (en) 2013-05-30
AU2010220058B2 (en) 2016-02-18
CN102292093A (zh) 2011-12-21
AU2010220058A1 (en) 2011-07-21
KR101682489B1 (ko) 2016-12-05
WO2010100653A3 (en) 2010-11-04
US20160074457A1 (en) 2016-03-17
WO2010100653A2 (en) 2010-09-10
US20110280951A1 (en) 2011-11-17
CA2751227C (en) 2021-10-26

Similar Documents

Publication Publication Date Title
CN102292093B (zh) 用于代谢综合症控制的选自绒毛戴星草和莽吉柿的混合物
Kanamoto et al. A black soybean seed coat extract prevents obesity and glucose intolerance by up-regulating uncoupling proteins and down-regulating inflammatory cytokines in high-fat diet-fed mice
Huang et al. Identification of compounds in adlay (Coix lachryma-jobi L. var. ma-yuen Stapf) seed hull extracts that inhibit lipopolysaccharide-induced inflammation in RAW 264.7 macrophages
US8703215B2 (en) Agents from Ficus hispida for the amelioration of metabolic syndrome and related diseases
US9345732B2 (en) Agents derived from Holoptelea integrifolia and their compositions for the control of metabolic syndrome and associated diseases
Cao et al. Phenolic constituents from black quinoa alleviate insulin resistance in HepG2 cells via regulating IRS1/PI3K/Akt/GLUTs signaling pathways
US20100111927A1 (en) Compositions Comprising Actinidia and Methods of Use Thereof
Xiong et al. Phenolic content, anti-inflammatory properties, and dermal wound repair properties of industrially processed and non-processed acai from the Brazilian Amazon
Turrini et al. Possible effects of dietary anthocyanins on diabetes and insulin resistance
TW201609123A (zh) 五層龍屬組成物、藉由其投藥之治療方法及其製備方法
US20140148399A1 (en) Compositions and methods for treating or ameliorating obesity or for reducing diabetic hypercholesterolemia
KR20060132970A (ko) 아디포넥틴 상승제
KR101152479B1 (ko) 탈지된 녹차씨 추출물을 유효성분으로 포함하는 항염 또는 항암 조성물
JP7301347B2 (ja) サーチュイン１活性化剤及びサーチュイン１活性化用皮膚化粧料
KR102025572B1 (ko) 고욤나무 잎 및 포도송이 줄기 추출물의 혼합물을 유효성분으로 함유하는 대사성 질환의 예방, 개선 또는 치료용 조성물
KR101119167B1 (ko) 체지방 억제에 유용한 약용식물 추출물을 포함하는 항 비만조성물
WO2018230931A2 (ko) 대사성 질환 예방 또는 치료용 조성물
KR20230092134A (ko) 금화규의 저온 추출물을 유효성분으로 포함하는 항비만용 조성물
Mallo et al. Effects of ethanolic extract of Cyperus esculentus (tiger nut) tubers on blood glucose level and lipid profile in alloxan-induced diabetes mellitus in male wistar rats
KR20110138732A (ko) 참죽나무 추출물을 함유하는 항염증 조성물
HK1159520B (en) Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome
HK1159520A (en) Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome
Peng et al. Health Benefits and Food Applications of Bioactive Constituents From Different Medicinal Parts (Bark, Leaf, and Fruit) of Lycium barbarum
KR101557557B1 (ko) 엔드리케리아 아노말라 추출물을 포함하는 항비만 조성물
JP2025033738A (ja) 植物混合抽出粉末を有効成分として含む筋肉損失関連疾病の予防または治療用組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant